Aviva’s Black Diamond Therapeutics BDTX Stock Holding History

Aviva’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-53,080	Closed	-$1.29M	–	876
2021 Q1	$1.29M	Buy	+53,080	New	+$1.43M	0.01%	755

Other funds holding BDTX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aviva's BDTX Position: Q2 2021 in Review

Aviva sold out of Black Diamond Therapeutics (BDTX) in Q2 2021, closing a stake of 53,080 shares — an estimated $1.29M sold.

Aviva first reported a position in BDTX in Q1 2021 and held it in 1 quarter. The position peaked at $1.29M in Q1 2021. 102 funds tracked by Wall St. Rank hold BDTX as of Q2 2021.

Aviva reported no remaining Black Diamond Therapeutics position as of Q2 2021 after selling out during the quarter.
Aviva sold 53,080 Black Diamond Therapeutics shares in Q2 2021, an estimated $1.29M.
Aviva first reported a position in Black Diamond Therapeutics in Q1 2021 and held it in 1 quarter.
Aviva's Black Diamond Therapeutics position peaked at $1.29M in Q1 2021.
102 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.